Agomelatine (VALDOXAN agomelatine 25 mg film coated tablet blister pack.)
Agomelatine risk profile, scheduling, and guidance for claims professionals and care workers . Also known as VALDOXAN agomelatine 25 mg film coated tablet blister pack., AGOMELATINE-WGR agomelatine 25 mg film coated tablet blister pack..
Agomelatine (brand names: VALDOXAN agomelatine 25 mg film coated tablet blister pack., AGOMELATINE-WGR agomelatine 25 mg film coated tablet blister pack.) is classified as Low risk (2 risk points) by AllMeds. It is a S4 medication under the TGA in Australia. Melatonergic antidepressant with sedating effects and potential for impaired cognition affecting workplace safety.
Key Takeaways
- TGA Schedule: S4 in Australia
- Risk level: Low (2 points)
- CNS depressant: May cause sedation, impair driving, and affect work capacity
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | S4 | Not PBS listed |
Risk Profile
Melatonergic antidepressant with sedating effects and potential for impaired cognition affecting workplace safety.
Regulatory and Compliance Guidance
When Agomelatine appears on a claimant's medication list, claims professionals should assess whether the prescribing is appropriate for the compensable injury, whether the duration is within guidelines, and whether there are interactions with other medications on the claim.
Work capacity impact: As a CNS depressant, Agomelatine may impair driving, operating machinery, and cognitive function. Work capacity certificates should reflect any medication-related restrictions.
Australia TGA / PBS / State Schemes
Classified as S4 under the Therapeutic Goods Administration (TGA).
United Kingdom NICE / MHRA / FPM
NICE guidelines recommend certain antidepressants (amitriptyline, duloxetine) for chronic pain management. For personal injury claims, antidepressant prescribing should be assessed for injury relatedness.
UK drug driving laws (Section 5A Road Traffic Act 2006) set specific limits for prescription drugs that cause impairment. Employers and occupational health advisors should assess fitness to work.
Need to assess this medication across your caseload?
Run a full risk assessment including Agomelatine interactions and compliance checks.
AllMeds gives you instant risk assessments, compliance checks, and automated letters for every medication on a claim.
No credit card required. No signup for your first 2 questions.
Medical Disclaimer: This content is for informational purposes for claims professionals and care workers. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions. Drug information is sourced from TGA, FDA, MHRA, PBS, NICE, and CDC databases and may not reflect the latest updates. AllMeds does not replace clinical judgement.